Clinical trials

RCSI Bahrain Clinical trials

RCSI Bahrain is equipped with highly-skilled and trained staff and research facilities to undertake observational, retrospective and interventional medicinal clinical trials in alignment with international regulatory guidelines at European and FDA standards.

Studies Conducted

• Convalescent plasma study in COVID. 1st National trial completed and published in Scientific Reports 2021 May 11;11(1):9927.
• Favipiravir trial in COVID. 2nd National trial completed and published in Scientific Reports 2022 Mar 23;12(1):4925.
• Booster vaccine study of Pfizer v Sinopharm booster in those with 2 doses of Sinopharm vaccine. 3rd National trial completed and submitted to Scientific Reports
• 5ALA commercial study sponsored by Photonamic – submitted to Journal of Clinical Biochemistry and Nutrition
• Dates v raisins study in Type 2 diabetes to show if there is a medicinal benefit of dates in comparison with raisins that have the same glycemic index. Published Nutrients 2022, 14(17), 3491;
• Ingestion of plasticizers over Ramadan in type 2 diabetes. Fully recruited and completed and awaiting analysis at the National Toxicology Center, Brisbane, Australia
• Asthma trial completed and undergoing analysis

Current Pharmaceutical partners with completed or ongoing studies:

• Novo Nordisk
• Pfizer
• Oramed USA

Please contact Professor Stephen Atkin for further details at satkin@rcsi.com.